<DOC>
	<DOCNO>NCT01397409</DOCNO>
	<brief_summary>This study conduct 3 stage . Stage 1 open-label , dose-escalation assessment safety AGN-150998 administer single intravitreal injection patient advance exudative Age-related Macular Degeneration ( AMD ) . Stage 2 Stage 3 randomize , double-masked , comparison safety treatment effect retinal edema best-corrected visual acuity ( BCVA ) AGN-150998 ranibizumab treatment-naive patient exudative AMD . Study medication administer need Stage 2 fixed-dosing schedule Stage 3 . The study objective ( 1 ) identify high tolerate dose AGN-150998 , ( 2 ) ass safety duration treatment effect retinal edema BCVA , ( 3 ) characterize systemic pharmacokinetic profile AGN-150998 .</brief_summary>
	<brief_title>Evaluation AGN-150998 Exudative Age-related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Exudative agerelated macular degeneration Bestcorrected visual acuity 20/32 20/320 study eye Nearsightedness 8 diopter Uncontrolled glaucoma study eye Cataract surgery Lasik within last 3 month Any active ocular infection inflammation</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>